Predictive validity of the SAD PERSONS and NO HOPE scales in a sample of suicide cases
Abstract
Introduction Suicide is a global public health issue necessitating evidence-based prevention strategies. Many individuals who die by suicide have had prior contact with healthcare services. Nearly half visit a primary care provider within a month before their death, and many visit emergency departments (EDs) frequently. Effective risk assessment in EDs is critical for suicide prevention but remains challenging. Inadequate risk assessments are a common error identified in suicide deaths. While clinical interviews are vital, risk assessment scales can support decision-making. The SAD PERSONS and NO HOPE scales are widely used but have limitations in predictive value. Materials and methods A case–control study using psychological autopsy (PA) was conducted from 2006 to 2016. Data were collected from 662 individuals in southern Spain, including 487 suicide cases and 175 controls. PAs involved interviews with close relatives and were conducted by trained psychiatrists or psychologists. The SAD PERSONS and NO HOPE scales were utilised, and data were analysed using sensitivity, specificity, and logistic regression to develop an improved predictive model. Results The SAD PERSONS scale showed high specificity but low sensitivity in predicting suicide risk. In the non-suicide group, 91.6% were classified as low risk. In the suicide group, nearly half were classified as low risk (49.6%). The modified SAD PERSONS scale showed similar results. The NO HOPE scale had low sensitivity but…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.